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Introduction: Colon cancer in pregnancy is uncommon. Only a small number of case reports have been published
in the literature on the use of chemotherapeutic drugs during pregnancy. Reports of such cases assist clinicians in
further investigating the use of chemotherapy in pregnancy.
Case presentation: FOLFOX-6 was administered to a pregnant, 33-year-old Saudi woman with metastatic colon
cancer from 22 to 30 weeks of gestation. Her cancer was diagnosed during her pregnancy. She tolerated the
chemotherapy well and delivered a full-term baby girl with no obvious harm, and normal development was
documented at her 2-year follow-up examination.
Conclusion: Colon cancer during pregnancy is not easily detected and is difficult to manage. A detailed
history and high clinical suspicion are needed in patients who present with symptoms and signs suggestive
of malignancy. A multidisciplinary approach with patient involvement is needed to decrease morbidity and
mortality caused by both treatment and the cancer in the mother and to limit side effects for the fetus. Further data
and long-term follow-up are needed to better understand the potential long-term side effects of chemotherapeutic
drugs on offspring.
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Colorectal cancer (CRC) in pregnancy is uncommon but
not rare [1], estimated to occur in 1 in 13,000 pregnan-
cies [2]. The initial symptoms of CRCs overlap with
expected physiological changes in pregnancy and can
easily be dismissed. The management of cancer in preg-
nancy raises ethical and medicolegal issues, and limited
literature exists to guide a management approach. Over
300 cases of colon cancer in pregnancy have been
reported to date. Four individual cases of chemotherapy
use during pregnancy have been reported [3–6], with
five additional cases reported by the International
Cancer and Pregnancy Registry (Cooper Medical School,
Rowan University, Camden, NJ, USA) [7]. We report a
case of a 33-year-old pregnant woman with metastatic* Correspondence: zmakoshi@gmail.com
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fetal harm.
Case presentation
A 33-year-old Saudi woman (gravida 9, para 8) pre-
sented to our emergency department at 11 weeks of
gestation with abdominal pain and increased flatus.
The patient had a history of bleeding per rectum for
2½ years, but she believed it was due to hemorrhoids
and failed to mention it to her primary care physician.
Abdominal ultrasound revealed a complex left ovarian
mass (19×12cm) extending up to the epigastrium with
hyperechoic solid components, and a small amount of
fluid was seen in the pelvis surrounding the appendix.
Her hemoglobin was 7.89g/dl, and her hematocrit was
25.2%. The result of a stool test for occult blood was
positive, and biochemistry showed iron deficiency anemia.
Her cancer antigen 125 (CA-125) level was elevated at
85.4kU/L. She underwent left salpingo-oophorectomy, ap-
pendectomy, and partial omentectomy by laparotomy at
13 weeks of gestation. Her pathological examination re-
vealed mucinous adenocarcinoma of the left ovary witharticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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Makoshi et al. Journal of Medical Case Reports  (2015) 9:140 Page 2 of 5signet ring component and serosa positive for tumor de-
posits, but no lymph node invasion.
The patient was counseled regarding termination of
her pregnancy for possible chemotherapy and computed
tomography (CT), and she agreed to undergo these
interventions. However, after a failed abortion with
vaginal administration of methotrexate, she refused fur-
ther intervention and decided to continue with her preg-
nancy. Abdominal CT showed a large rectosigmoid
tumor measuring 4.2cm×4.7cm×6.3cm with mildly en-
larged regional lymph nodes and four hypodense meta-
static liver lesions. The patient presented 2 weeks before
her next appointment with fresh bleeding per rectum. A
colonoscopy revealed a large rectal mass obstructing the
lumen. A pathological examination showed fragments of
adenomatous mucosa with high-grade dysplasia and foci
of possible invasion. Her diagnosis was established as a
case of colonic KRAS-mutant positive adenocarcinoma
with left ovarian and liver metastases. The patient’s case
was discussed with maternal-fetal medicine clinicians,
and a recommendation was made to start a bimonthly
adjuvant FOLFOX-6 chemotherapy regimen consisting
of 2-hour infusion of oxaliplatin 100mg/m2 and leu-
covorin 200mg/m2, 5-fluorouracil (5-FU) 400mg/m2
bolus, and a 5-FU 2400mg/m2 46-hour infusion.
She was started on her first cycle of FOLFOX-6
chemotherapy at 22 weeks. She developed mild periph-
eral paresthesia in her upper and lower extremities that
resolved 3 days after chemotherapy. Her CA-125 level
decreased to 29.1kU/L. After five cycles of chemotherapy
were completed, abdominal magnetic resonance imaging
(MRI) showed an interval reduction of approximately
30% in the size of the previously seen four liver meta-
static lesions. There was mild interval reduction in
the size of the rectal mass, with almost stable re-
gional lymphadenopathy. The patient completed six
cycles of chemotherapy, and a decision was made to
withhold further chemotherapy until after delivery.
Monthly ultrasound for fetal well-being revealed nor-
mal fetal growth and development.
The patient was admitted at 38 weeks of gestation for
induction of labor. She had a vaginal delivery of a
healthy infant girl of birth weight 2400g with Apgar
scores of 9 and 10 at 1 and 5 minutes, respectively. The
patient and her infant had no immediate complications
post-partum. Two weeks following delivery, the patient
received her seventh cycle of FOLFOX-6 chemotherapy.
The patient underwent colostomy and cholecystectomy
with hepatic metastasectomy followed by six cycles of ad-
juvant FOLFIRI chemotherapy (folinic acid, 5-fluorouracil
and irinotecan). Abdominal and chest CT with intraven-
ous contrast performed at 15 months post-delivery re-
vealed further hepatic lesions, pulmonary nodules and
right hydronephrosis caused by a pelvic mass. A decisionwas made to continue with palliative chemotherapy.
Follow-up at 24 months with repeat scans showed
evidence of stable hepatic and pulmonary lesions with
an interval increase in the size of the patient’s pelvic
mass. The child was assessed in the pediatric clinic at 1
month and again at 24 months and was found to have
met developmental milestones without any recognizable
complications, and annual follow-ups were scheduled.
Discussion
In a review of 205 cases of CRC in pregnancy, the mean
age at diagnosis was 31 years and 85% of these cancers
were below the peritoneal reflection [8], as in our pa-
tient. CRC during pregnancy is believed to affect the
chances of the pregnancy’s being carried to full term
with delivery of a live infant [9]. Presenting symptoms of
CRC, such as abdominal pain, constipation, vomiting
and anemia, may be attributed to common gastrointes-
tinal complaints in pregnancy. Rectal bleeding may be
attributed to hemorrhoids, as occurred in our patient. A
diagnosis is often delayed until after the 20th week of
gestation [9], and patient prognosis at presentation is
usually poor [10], with most patients presenting after
metastasis has occurred in Dukes stages C and D [8].
The diagnosis and staging of cancer in pregnancy can
prove to be a challenge for the treating physician.
Carcinoembryonic antigen levels are usually normal or
mildly elevated in pregnancy [11]; therefore, they can be
used in the same manner as they are in non-pregnant
patients. Imaging modalities considered safe in preg-
nancy include diagnostic X-rays [12], ultrasounds [13],
sigmoidoscopies [14] and MRI [15], whereas others pose
a considerable risk to the fetus, such as CT, barium en-
emas and radioisotope scans, owing to the higher doses
of ionizing radiation delivered to the fetus.
Radiation effects are dependent largely on both the pa-
tient size and the radiation dose; however, gestational
age is not significantly linked to the fetal dose of radi-
ation [16]. Although a single abdominal or pelvic CT
scan delivers a radiation dose of approximately 24 mGy
to the fetus [16], which is considered below the safety
threshold [17], as a general rule, radiation imaging, as
well as chemotherapeutic treatments and primary sur-
geries, is best delayed if possible until the second trimes-
ter, when organogenesis is complete [18, 19] and the size
of the uterus allows proper surgical intervention [20].
Clinical guidelines for the management of cancer in
pregnancy are available in the literature [2, 21]. However,
these guidelines are based mostly on case reports of, and
guidelines for, non-pregnant patients. Treatment is
aimed at starting therapy for the mother as soon as pos-
sible, weighing the decision of early delivery of the fetus
against completion of fetal growth and lung maturity. It
is recommended that delivery occur after 32 to 35 weeks
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deemed satisfactory [2]. The decision to deliver by
cesarean section or vaginally depends on the presence
of obstruction of the delivery canal or obstetric indi-
cations; cancer per se is not an indication to perform
a cesarean section.
The recommendation for resectable CRC diagnosed
before 20 weeks of gestation is surgical resection to de-
crease the chance of dissemination occurring later in the
pregnancy [22]. Surgical resection can often be per-
formed without the need for a hysterectomy and without
disturbing the pregnancy [8]. If diagnosis occurs after 20
weeks of gestation, surgery can be postponed, allowing
for fetal lung maturity to be achieved and facilitating
surgical exploration [23]. If cesarean section is the
decided method of delivery, colorectal tumor resection
can be performed during delivery, or it can be delayed
for several weeks post-partum to allow for involution of
the uterus and resolution of vascular engorgement of
pregnancy [23].
In our patient, a decision was made to perform a left
salpingo-oophorectomy at 13 weeks of gestation because
of evidence of ovarian metastases. The incidence of ovar-
ian metastases in pregnant patients with CRC is 25% [24]
and is associated with a poor prognosis [25]. Owing to the
higher frequency of ovarian metastases, it is recom-
mended that bilateral salpingo-oophorectomy be per-
formed at the time of primary tumor resection [26, 27];
however, this approach is associated with a high inci-
dence of spontaneous abortion, particularly in the first
trimester [28], and risks as well as desire for future
pregnancies should be discussed with the patient.
Although radiation therapy can be considered in the
treatment of cancers located remote from the fetus, radi-
ation doses required for treatment of cancers located in
the pelvis carry a serious risk of severe or lethal effects
for the fetus and are recommended to be postponed
until after delivery or pregnancy termination [29].
Decisions to use chemotherapy during pregnancy are
weighed against the risk of teratogenicity and the limited
clinical evidence of late effects. The decision relies on
the analysis of risks and benefits and clearly defined aims
of using chemotherapy, which are often to prolong the
gestational age of the fetus and to improve the mother’s
quality of life. The evidence for selection and use of
chemotherapeutic agents during pregnancy is limited,
owing to the relatively low incidence of this treatment.
However, FOLFOX regimes are often used in the treat-
ment of advanced CRC, as recommended by National
Comprehensive Cancer Network guidelines for patients
with advanced or metastatic disease [30]. The FOLFOX
regime consists of oxaliplatin, leucovorin and 5-FU. The
U.S. Food and Drug Administration safety rating for the
use of oxaliplatin and 5-FU during pregnancy is class D.The FOLFOX regimes are considered the gold standard
for treating advanced CRC in non-pregnant patients [31].
In three case studies, authors have reported the use of
FOLFOX regimes to treat CRC during pregnancy [3–5].
Gestational age at initiation of chemotherapy ranged
from 13 weeks [5] to 24 weeks [4], and all reported posi-
tive fetal outcomes. The follow-up periods ranged from
11¾ months [4] to 3½ years [3], and all children were
reported to be within the normal limits for height,
weight and neurological development. The mothers were
started on FOLFIRI regimes once delivery had occurred,
and two underwent surgical resection [3, 5]. Maternal
outcomes varied from being disease-free at 1 year [3],
dying 1 year after diagnosis (6 months post-delivery) [4]
and dying 5 months after diagnosis (16 weeks post-
delivery) [5]. Only one recent case report [6] included in
our present literature review described use of the
FOLFIRI regime, consisting of irinotecan, leucovorin
and 5-FU, during pregnancy, followed by FOLFOX post-
delivery. Oxaliplatin was excluded from first-line therapy
in that patient because of its neurotoxicity side effects.
However, irinotecan was administered for only three
cycles, which limits the results.
The low incidence of cancer during pregnancy and a
patient’s decision to abort her pregnancy limit the estab-
lishment of high-level evidence for chemotherapeutic
guidelines during pregnancy [32]. Congenital fetal
abnormalities have been reported in a number of preg-
nancies in which 5-FU was administered in the first
trimester because of organogenesis taking place at this
point of fetal development [33–35]. This incidence can
range from 14% to 19%, depending on the drug used
[36]. This rate is reduced significantly to 1.3% when ad-
ministration occurs in the second and third trimesters
[36]. This is evident in past case reports, as well as in
our patient, when chemotherapy was administered from
the second trimester onward and no fetal malformations
were reported [3–5]. This is concurrent with previous
literature reports of healthy neonates born after being
exposed to 5-FU during the second and third trimesters
only [37, 38]. However, follow-up during school years in
such cases would assist in evaluation of any side effects
that may present later in development.
Less positive maternal outcomes were reported in two
cases [4, 5]. Only one study reported the mother to be
disease-free at 1 year [3]. In that patient, CRC was de-
tected during the first trimester (12 weeks of gestation),
giving some evidence of a better maternal outcome with
early detection and before extensive dissemination.
However, suspicion of malignancy during pregnancy re-
mains low among physicians. A recent case report [39]
involved a 37-year-old woman admitted with suspicion
of a ruptured membrane who underwent an emergency
cesarean section. She was discharged and returned post-
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and underwent a colonoscopy that revealed a large tumor
of the transverse colon.Conclusions
The diagnosis of CRC during pregnancy continues to be
a challenge for clinicians, owing to the overlap of symp-
toms. A detailed history, judicious clinical suspicion and
patient education cannot be overstated. The diagnostic
workup can be safe for both mother and fetus, and, once
a diagnosis is made, treatment should involve a multi-
disciplinary team and the mother’s wishes regarding her
pregnancy. Also, the benefits and risks of treatment
should be discussed. Termination of pregnancy is advis-
able for early and aggressive treatment of CRC when
possible. Available evidence supporting the use of
FOLFOX chemotherapy for CRC from the second term
onward, although limited, shows relatively no to minor
effects on mother and fetus in the short term. However,
the long-term effects of this treatment remain unknown.
Follow-up of infants in later childhood and adoles-
cence, as the central nervous system continues to de-
velop, with additional reporting of cases is needed to
establish the safety of chemotherapeutic treatment of
CRC during pregnancy.Consent
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for publication of this case report and accompanying
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